This letter presents the first quantitative, in vivo, transcutaneous glucose measurements using surface enhanced Raman spectroscopy (SERS). Silver film over nanosphere (AgFON) surfaces were functionalized with a mixed selfassembled monolayer (SAM) and implanted subcutaneously in a Sprague-Dawley rat. The glucose concentration was monitored in the interstitial fluid. SER spectra were collected from the sensor chip through the skin using spatially offset Raman spectroscopy (SORS). The combination of SERS and SORS is a powerful new approach to the challenging problem of in vivo metabolite and drug sensing.
The field of surface enhanced Raman spectroscopy (SERS) research has undergone a renaissance in the past decade, especially in the area of biological applications, due to the great advances made in the fabrication of large area, reproducible, longlived SERS substrates.
1 Biological applications of SERS ranging from cancer detection 2, 3 to the study of basic cell processes 4, 5 have been vigorously pursued. However, most of this work has been carried out in vitro, due to the challenges posed by the complexity of the in vivo environment. These include (1) placement of the SERS-active surface in vivo; (2) the numerous interfering agents that can potentially adsorb to the SERS-active surface rendering it unresponsive to glucose or other target analytes; and (3) the natural inflammation and foreign body response (FBR) that occurs.
The majority of in vivo SERS work has been qualitative in nature and has used SERS as an alternative to fluorescence labeling. 6, 7 In contrast, we demonstrated that SERS can be used in vivo to directly and quantitatively detect biological targets. The example pursued in our laboratory was an implantable SERS glucose sensor. [8] [9] [10] [11] [12] [13] The SERS sensor utilizes the ability of Raman spectroscopy to specifically detect glucose and mitigates the inherently low intensity of Raman scattering by using surfaceenhancement to amplify the intensity by factors of 10 6 -10 8 . In previous in vivo studies, a dorsal skinfold chamber was implanted in a rat for optical access to the SERS sensor. 8, 12 At that time, a windowed chamber was the only method available that allowed collection of the SER scattering signal. While an effective laboratory tool, a more elegant solution was needed to push the use of an implantable SERS sensor toward clinical use.
The approach chosen was to remove the window and directly collect SER scattering transcutaneously. However, introducing the skin into the optical detection system presents a new set of challenges. The large refractive index change between skin and air immediately produces intensity losses due to back reflections. 14 Within the skin layers, light is further attenuated due to multiple scattering and absorption events. For example, the lipids in cell walls scatter light and blood absorbs light in the 400-700 nm region. Similarly, the protein keratin and the pigment melanin can both scatter and absorb light. 15, 16 These difficulties are further compounded when illuminating and collecting from a subcutaneous sample since both the input laser excitation light must pass through the skin and the output Raman scattered light must pass back out through the skin to reach the detector. To address these problems, the approach chosen was spatially offset Raman spectroscopy (SORS).
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In SORS, Raman scattered light is collected from regions offset from the point of laser excitation at the sample. 17 In contrast, for normal Raman spectroscopy the excitation and collection points are coincident so that the surface of the sample gives the greatest contribution to the Raman spectrum. When spectra are collected some distance away from the excitation point, spectral features originating from underlying layers give a greater contribution than the surface. 18, 19 Combining the sensitivity of SERS with the depth resolution of SORS yields a powerful new tool for biomedical sensing. During the time this research was conducted, Stone et al. independently combined SERS and SORS (SESORS) to capture in vitro spectra of NIR dye-tagged silver nanoparticles injected into pork tissue. 20 The conjugated dye was chosen to give a large signal when using near-infrared (NIR) excitation. This allowed for straightforward measurement of the tagged particles and determination of a detection threshold for particle density. The SESORS experiments reported here significantly extend the initial report 20 by demonstrating the acquisition of transcutaneous spectra in vivo and demonstrate an initial attempt at quantitative glucose detection.
EXPERIMENTAL SECTION
Materials. All the chemicals were reagent grade or better and used as purchased. Silver pellets (99.99%) were purchased from the Kurt J. Lesker Co. ) from a Millipore system (Marlborough, MA) was used. Glucose, decanethiol (DT), and 6-mercapto-1-hexanol (MH) were purchased from Sigma-Aldrich (St. Louis, MO).
AgFON Fabrication and Incubation Procedure. The titanium substrates were soaked in 6:1 H 2 O/H 2 SO 4 for 2 min, rinsed, and sonicated in a 5:1:1 H 2 O/30% H 2 O 2 /NH 4 OH solution for 10 min. Approximately 10 µL of nanosphere solution was dropcoated onto clean titanium substrates and allowed to dry under ambient conditions. Ag films (200 nm thick) were deposited over the nanosphere layer using a home-built thermal deposition system to form silver film over nanosphere (AgFON) substrates. The substrates were incubated in 1 mM DT in ethanol for 45 min and transferred to 1 mM MH in ethanol for at least 12 h to form a mixed DT/MH SAM. The AgFONs were kept in the 1 mM MH solution until used.
Instrumentation. The SORS system (Figure 1 ) was adapted from that described by Matousek. 21 A fiber coupled diode laser (λ ex ) 785 nm, P ) 60 mW, Newport Corp., Irvine, CA) was used as the illumination source, and an interference filter (Semrock, Rochester, NY) isolated the laser line. Optical quality prisms and mirrors (Thor Laboratories, Newton, NJ) were used to guide the laser to the sample. Identical lenses (D ) 50.8 mm, f ) 60.0 mm, Thor Laboratories) were used to collect the scattered light and focus it into the fiber bundle. Between the lenses, a notch filter (Semrock, Rochester, NY) was used to reject the Raleigh scattered light. Between the second focusing lens and the fiber bundle, another notch filter and long pass filter (Semrock, Rochester, NY) were used to further exclude the elastically scattered light.
The fiber bundle was a custom-made bundle (C-Technologies, Bridgewater, NJ) consisting of 26 fibers arranged in a 6 mm diameter circle at the collection head and aligned vertically at the detection end (Figure 1 inset) . The Raman spectrometer was an Acton LS785 spectrograph paired with a Pixis 400BR CCD camera (Princeton Instruments, Trenton, NJ). Replacing the custom fiber bundle with a standard fiber bundle allowed the SORS system to function as a conventional Raman spectroscopy system.
In Vivo Transcutaneous SESORS. All surgical procedures followed protocols filed with the Northwestern University IACUC. A male Sprague-Dawley rat (453 g) was anesthetized with isoflurane (1.5-3%) throughout the surgical procedure and the duration of the experiment. The animal was checked for pain reactions by toe-tug and blink tests. None were observed. After the anesthetic had taken effect, the side and belly of the animal were shaved and chemically depilated. An incision was made in the skin and a pocket was blunt dissected into the subcutaneous space. A single DT/MH AgFON was placed in the pocket and the incision was closed with surgical clips. The rat was placed in the SORS apparatus and SESOR spectra were acquired. Excitation wavelength (λ ex ) was 785 nm; excitation power (P ex ) was 50 mW, and acquisition time (t acq ) was 20 s.
In Vivo Transcutaneous SESORS Glucose Measurements. Experiments were conducted to gauge the viability of transcutaneous SESORS as a data collection technique for glucose measurements. A male rat (427 g) was anesthetized as previously detailed and cannulated using PE 50 tubing for drug/glucose injections and blood glucose measurements, respectively. An AgFON sensor was implanted as described above; all incisions were shut with surgical clips, and the rat was placed in the SORS system. Following the experiment, the animals were sacrificed with an overdose of sodium pentabarbitol (150 mg/kg) and bilateral thorachotomy. The glucose concentration in the rat was increased through intermittent intravenous infusion (1 g/mL in sterile PBS) over the course of the experiment and decreased by IV insulin injection (0.5 mL of 2 U/mL). A droplet of blood was drawn from the rat, the glucose level was measured with the Ascensia Elite home blood glucometer, and corresponding SE-SORS measurements were taken (λ ex ) 785 nm, P ex ) 50 mW, t acq ) 2 min). To keep the osmotic pressure of the rat at normal physiological levels, a volume of BSA (0.8% in sterile saline) equal to the blood removed was injected following each blood glucose measurement. The data were collected and analyzed by the partial least-squares leave-one-out (PLS-LOO) method described in our previous papers. 8, [10] [11] [12] [13] 22, 23 The calculations were performed with MATLAB (MathWorks, Inc., Natick, MA) and PLS_Toolbox (Eignevector Research, Inc., Manson, WA).
RESULTS AND DISCUSSION
SESORS from SAM Functionalized AgFON Surfaces. In vivo transcutaneous SESORS spectra of a DT/MH functionalized AgFON were compared with the corresponding spectra of the functionalized AgFON taken ex vivo with the spectrometer in standard mode. Figure 2A shows the SER spectrum of a DT/MH AgFON. Figure 2B shows the in vivo SESOR spectrum of an implanted DT/MH AgFON. Representative peaks can be seen at 1426, 1063, 881, and 700 cm -1
. The maximum peak intensity was 160 ADU s -1 mW -1 in the standard SERS spectrum and 4 ADU s -1 mW -1 in the transcutaneous SORS spectrum. Thus, the SERS signal is attenuated by approximately 95% due to the presence of skin; however, all spectral features from the DT/ MH AgFON remain easily observable with a high signal-tonoise ratio (S/N).
Clarke Error Grid Analysis and Time Course Comparison. The Clarke error grid was introduced over 20 years ago 24 and has become a common standard to compare the accuracy and performance of glucose sensors. 25 Predicted concentrations are plotted versus measured concentrations, and the graph is divided into five different zones. Measurements that fall in zone A are considered clinically accurate measurements, in zone B they lead to benign or no action by the patient, in zone C they lead to unnecessary action, in zone D they lead to a lack of action when glucose value correction is necessary, and, finally, in zone E they lead to actions that are opposite to those that are clinically necessary. Accurate sensing only results in data points within the A and B ranges of the grid. 26 Figure 3A shows a Clarke error grid analysis from in vivo transcutaneous SESORS glucose measurements. Unlike previous in vivo experiments, all measurements were not taken from a single position on the sensor, since using the annular fiber bundle to collect spectra inherently leads to a spatially averaged collection from a circular area instead of a single point. In addition, no holder was required to secure the sensor in position and the sensor was allowed to move with the body of the rat as it breathed. Thus, relative spatial motion between the sensor chip and the SORS probe was NOT problematic. In total, 30 measurements were taken. Twenty-one data points were correlated with the Ascensia Elite readings and used to create the calibration set. Nine measurements were used as independent data points for the validation set. A total of 7 of the 9 validation points fell within the A and B ranges, showing good predictive results. The mean absolute relative difference values for calibration was 16.6% and for validation 34.6%. Higher error (RMSEC ) 58.11 mg/dL (3.23 mM) and RMSEP ) 96.35 mg/dL (5.35 mM)) is seen than in previous in vivo results, 8, 12 but given the added optical dispersion of the skin and the displacement of the sensor during the experiment this is not unexpected. It should be noted that these RMSEC values are similar to those reported in our earlier in vitro experiments. 10 The error can be improved by increasing the number of data points in the calibration. Though not quantitatively identical, both effectively track the decrease of glucose concentration after dosing with insulin. The quantitative discrepancy between the sensors can be explained in part by their different sensing environments. The Ascensia Elite measures blood glucose concentration while the SERS sensor detects the concentration of glucose in the interstitial fluid. It is agreed that there is a delay associated with diffusion of glucose from blood vessels into the interstitial fluid, though estimates are inexact. 27 Therefore, it is unsurprising that the predicted values of the Ascensia Elite and the SERS sensor do not quantitatively agree. Points 6 and 8, which are circled, show a marked degree of deviation. A variety of sources of error can contribute to this deviation and will be investigated further in future experiments. Nevertheless, the extent of agreement is highly encouraging. In addition to the different environments that the two sensors sample, the use of the Ascensia Elite as the calibration method for the SERS measurements also contributed to the differences observed. The scatter in the SERS measurements incorporates the error inherent in the Ascensia Elite, increasing the perceived SERS error. The current standard for accuracy of home blood glucose monitoring systems (ISO 15197) states that device measurements should fall within 20% of laboratory standard results 95% of the time (this corresponds to zone A in the Clarke error grid). This standard allows for large variations in glucose readings. Studies of commercial home glucose meters similar to the one used in our experiments have shown that most do not even meet this standard. 26, 28 In a test of six home glucose meters, only one reached the ISO standard, with 96% of measurements falling within the A region. The least accurate meter showed only 67% of measurements falling within the A region. In addition to accuracy, home glucose meter precision was also measured. The precision varied from 5.5% to 8.4% (7.7-11.1 mg/dL). 28 Because of the calibrating method used in our study, the error in both the precision and the accuracy of the electrochemical sensing method contributed to even greater error in SERS measurements. Despite the numerical disparity, the results show that the SERS sensor is viable in vivo and can detect glucose concentration fluctuations over time.
CONCLUSIONS
This work details the first proof-of-concept experiments for in vivo transcutaneous SER spectra taken using SORS. These results represent a significant step on the road toward an implantable, real time, continuous glucose sensor based on SERS. Current implanted amperometric sensors indirectly detect glucose through the flux of the molecule to the sensor surface. [29] [30] [31] Our SERS approach allows us to detect glucose directly, giving us the potential to exceed the capabilities of current implantable electrochemical glucose monitoring systems. We believe that further amplification of SERS signals by 100 times is possible with the next generation of substrates being developed in our laboratory. 32 The greater the SERS enhancement factor, the greater will be the accuracy of the SERS glucose sensor. Experiments are now in progress to test these new SERS substrates as well as new surface modification strategies designed to improve the reproducibility and longevity of the SERS sensor chip beyond levels currently demonstrated. Further, we are actively exploring modified surfaces with new partition/capture layers to expand the number of biological targets accessible to in vivo SERS. In light of these findings, it is now clear that skin is no longer an insurmountable barrier to quantitative in vivo SERS biosening.
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